- Home
- LICN vs TOVX Comparison
LICN vs TOVX Comparison
Compare LICN & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICN
- TOVX
- Stock Information
- Founded
- LICN 2004
- TOVX 2001
- Country
- LICN China
- TOVX United States
- Employees
- LICN N/A
- TOVX N/A
- Industry
- LICN
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- LICN
- TOVX Health Care
- Exchange
- LICN Nasdaq
- TOVX Nasdaq
- Market Cap
- LICN 3.1M
- TOVX 3.8M
- IPO Year
- LICN 2023
- TOVX 2006
- Fundamental
- Price
- LICN $4.44
- TOVX $0.50
- Analyst Decision
- LICN
- TOVX Hold
- Analyst Count
- LICN 0
- TOVX 1
- Target Price
- LICN N/A
- TOVX N/A
- AVG Volume (30 Days)
- LICN 22.6K
- TOVX 183.1K
- Earning Date
- LICN 01-01-0001
- TOVX 08-12-2025
- Dividend Yield
- LICN N/A
- TOVX N/A
- EPS Growth
- LICN N/A
- TOVX N/A
- EPS
- LICN N/A
- TOVX N/A
- Revenue
- LICN $41,477,000.00
- TOVX N/A
- Revenue This Year
- LICN N/A
- TOVX N/A
- Revenue Next Year
- LICN N/A
- TOVX N/A
- P/E Ratio
- LICN N/A
- TOVX N/A
- Revenue Growth
- LICN 4.32
- TOVX N/A
- 52 Week Low
- LICN $2.60
- TOVX $0.40
- 52 Week High
- LICN $488.00
- TOVX $7.37
- Technical
- Relative Strength Index (RSI)
- LICN 53.94
- TOVX 45.57
- Support Level
- LICN $4.02
- TOVX $0.42
- Resistance Level
- LICN $4.41
- TOVX $0.48
- Average True Range (ATR)
- LICN 0.25
- TOVX 0.03
- MACD
- LICN 0.05
- TOVX 0.02
- Stochastic Oscillator
- LICN 92.57
- TOVX 88.67
About LICN Lichen China Limited
Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.